Davide Arillotta
Overview
Explore the profile of Davide Arillotta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Arillotta D, Guirguis A, Corkery J, Scherbaum N, Schifano F
Brain Sci
. 2021 Aug;
11(7).
PMID: 34356142
The restrictive measures adopted during the COVID-19 pandemic modified some previously consolidated drug use patterns. A focus on social networks allowed drug users to discuss, share opinions and provide advice...
12.
Catalani V, Corkery J, Guirguis A, Napoletano F, Arillotta D, Zangani C, et al.
Eur Neuropsychopharmacol
. 2021 Apr;
49:69-92.
PMID: 33857740
Psychedelics alter the perception of reality through agonist or partial agonist interaction with the 2A serotoninergic receptor. They are classified as phenethylamines, tryptamines and lysergamides. These classes, according to the...
13.
Catalani V, Arillotta D, Corkery J, Guirguis A, Vento A, Schifano F
Front Psychiatry
. 2021 Feb;
11:632405.
PMID: 33633599
COVID-19-related disruptions of people and goods' circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of...
14.
Schifano F, Chiappini S, Miuli A, Corkery J, Scherbaum N, Napoletano F, et al.
Exp Neurol
. 2021 Feb;
339:113638.
PMID: 33571533
The use of several new psychoactive substances (NPS) has become very popular and is posing global health risks. Chemically and pharmacologically diverse molecules are constantly emerging and are presenting with...
15.
Fusar-Poli L, Rodolico A, Sturiale S, Carotenuto B, Natale A, Arillotta D, et al.
Clin Psychopharmacol Neurosci
. 2021 Jan;
19(1):26-45.
PMID: 33508786
The second-to-fourth digit ratio (2D:4D) is an indirect, retrospective, non-invasive measure that correlates negatively with intrauterine exposure to testosterone. The present meta-analysis aimed to evaluate if 2D:4D differs between patients...
16.
Napoletano F, Schifano F, Corkery J, Guirguis A, Arillotta D, Zangani C, et al.
Front Psychiatry
. 2020 Oct;
11:546796.
PMID: 33024436
Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit...
17.
Arillotta D, Schifano F, Napoletano F, Zangani C, Gilgar L, Guirguis A, et al.
Front Neurosci
. 2020 Apr;
14:149.
PMID: 32256304
Background: A wide range of novel psychoactive substances (NPSs) are regularly searched and discussed online by e-psychonauts. Among NPSs, the range of prescription/non-prescription opioids (fentanyl and non-fentanyl analogs) and herbal...
18.
Zangani C, Schifano F, Napoletano F, Arillotta D, Gilgar L, Guirguis A, et al.
Curr Neuropharmacol
. 2020 Mar;
18(10):966-1051.
PMID: 32116194
Background: A wide range of novel psychoactive substances (NPS) is regularly searched and discussed online by web-based drug enthusiasts (i.e. the e-psychonauts). Among NPS, the range of synthetic cannabinoids (SC;...
19.
Schifano F, Napoletano F, Arillotta D, Zangani C, Gilgar L, Guirguis A, et al.
Br J Clin Pharmacol
. 2019 Nov;
86(3):410-419.
PMID: 31674690
Aims: Within the new psychoactive substances (NPS) scenario, several hundred different molecules, mostly including synthetic cannabinoids and cathinones, have been identified so far. The aims of the paper were to:...
20.
Fusar-Poli L, Brondino N, Rocchetti M, Petrosino B, Arillotta D, Damiani S, et al.
Psychiatry Res
. 2019 May;
276:203-209.
PMID: 31102885
Autism spectrum disorder (ASD) is a group of life-long neurodevelopmental conditions with a prevalence of 1.5% in developed countries. Beside core symptomatology, ASD people are frequently affected by psychiatric comorbidities...